

# Dedee Murrell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8603576/dedee-murrell-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213  
papers

6,342  
citations

42  
h-index

76  
g-index

299  
ext. papers

7,880  
ext. citations

3.2  
avg, IF

5.91  
L-index

#	Paper	IF	Citations
213	Dermatoethics: Nepotism in Dermatology Residencies.. <i>Journal of the American Academy of Dermatology</i> , <b>2022</b> ,	4.5	
212	Biological medication in atopic dermatitis.. <i>Expert Opinion on Biological Therapy</i> , <b>2022</b> , 1-7	5.4	1
211	Training and Retaining Physician-Scientists in Dermatology: Australia.. <i>JID Innovations</i> , <b>2022</b> , 2, 100074		0
210	Sebaceous cell carcinoma presenting as an ocular Marjolin ulcer following immunosuppression for a chemical burn from a common alkaline cleaning agent.. <i>Canadian Journal of Ophthalmology</i> , <b>2022</b> ,	1.4	
209	Osteoporosis and Psoriasis: A Literature Review.. <i>Clinical and Experimental Dermatology</i> , <b>2022</b> ,	1.8	1
208	How do experts treat patients with bullous pemphigoid around the world? An international survey.. <i>JID Innovations</i> , <b>2022</b> , 100129		
207	Allergic contact dermatitis to miconazole for nipple candidiasis.. <i>Contact Dermatitis</i> , <b>2022</b> ,	2.7	0
206	Mental health, insomnia and suicidal ideation during treatment with apremilast.. <i>Australasian Journal of Dermatology</i> , <b>2022</b> ,	1.3	0
205	Comparison of effectiveness of topical tacrolimus 0.1% vs topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14675	2.2	1
204	A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). <i>JAAD International</i> , <b>2021</b> , 2, 134-152	0.9	0
203	Heralding change within dermatology: Response of the International Journal of Women's Dermatology (IJWD) to the twin pandemic of racism. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 125-126	2	2
202	Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e412-e414	4.6	15
201	Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI $\geq$ 6) analysis of randomized phase 2B study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 1562-1568	4.6	9
200	Are biosimilars for pemphigus safe?. <i>Clinical and Experimental Dermatology</i> , <b>2021</b> , 46, 942-943	1.8	1
199	Managing epidermolysis bullosa during the coronavirus pandemic: Experience and ideals. <i>Clinics in Dermatology</i> , <b>2021</b> , 39, 369-373	3	
198	Beyond the skin: disease parameters in pemphigus. <i>Italian Journal of Dermatology and Venereology</i> , <b>2021</b> , 156, 147-150	1.2	0
197	Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1523-1537	4.5	5

196	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 745-755	4	13
195	Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1507-1519	4.5	4
194	What instruments should we add to our toolbox for measuring the severity and control of eczema?. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 13-14	4	
193	Impact of COVID-19 on inpatient dermatology consults in an Australian tertiary hospital. <i>Australasian Journal of Dermatology</i> , <b>2021</b> , 62, 427-428	1.3	0
192	Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 18-27	4.5	3
191	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 1750-1764	4.6	10
190	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 1926-1948	4.6	16
189	Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, e47-e48	4.5	
188	Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 1161-1167	4.5	8
187	Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 1107-1109.e2	11.5	8
186	Ectropion surgery might not be a long-term solution for harlequin ichthyosis. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14646	2.2	0
185	Authors' reply to the comment "Treatment considerations for patients with pemphigus during the COVID-19 pandemic". <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, e61-e62	4.5	2
184	An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study. <i>Experimental Dermatology</i> , <b>2021</b> , 30, 1675-1685	4	1
183	Cardiac Involvement in Epidermolysis Bullosa <b>2021</b> , 33-48		
182	The Importance of Cardiac Assessment in the Era of Biologic Therapies for Psoriasis <b>2021</b> , 419-430		
181	Over-expression of stromal periostin correlates with poor prognosis of cutaneous squamous cell carcinomas. <i>Experimental Dermatology</i> , <b>2021</b> , 30, 698-704	4	4
180	Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 1-14	4.5	7
179	Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , <b>2021</b> , 1-7	0.8	

178	State-of-the-art review of human autoimmune blistering diseases (AIBD). <i>Veterinary Dermatology</i> , <b>2021</b> , 32, 524-e145	1.8	
177	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 708071	4.9	1
176	Assessing the quality of life in the families of patients with epidermolysis bullosa: The mothers as main caregivers.. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 721-726	2	2
175	Shedding light on the impact of hidradenitis suppurativa on women and their families: A focus of the .. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 661-663	2	0
174	Evaluating diversity in Clinics in Dermatology: Diversity in clinics in dermatology: M. Sun et al.. <i>Clinics in Dermatology</i> , <b>2021</b> , 39, 1064-1066	3	
173	Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey. <i>Pediatric Dermatology</i> , <b>2021</b> , 38, 1198-1201	1.9	2
172	The impact of gender in mentor-mentee success: Results from the Women's Dermatologic Society Mentorship Survey. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 398-402	2	1
171	Embracing diversity in dermatology: Creation of a culture of inclusion in dermatologic publishing. <i>International Journal of Women's Dermatology</i> , <b>2021</b> , 7, 371-377	2	0
170	Conducting dermatology clinical trials during the COVID-19 pandemic. <i>Clinics in Dermatology</i> , <b>2021</b> , 39, 104-106	3	2
169	Assessment of published literature regarding skin of color in Pediatric Dermatology.. <i>Pediatric Dermatology</i> , <b>2021</b> , 38, 1604-1605	1.9	
168	A dermatologist's perspective of the COVID-19 outbreak. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13538	2.2	8
167	The response of the Women's Dermatologic Society and the to the COVID-19 pandemic. <i>International Journal of Women's Dermatology</i> , <b>2020</b> , 6, 129-130	2	
166	Use of face masks in dermatology department during the COVID-19 outbreak. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13521	2.2	4
165	Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 944-945	4	3
164	Update on COVID-19 effects in dermatology specialty. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13523	2.2	10
163	Restructuring an academic dermatology practice during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13684	2.2	4
162	Virtual conferences of dermatology during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13774	2.2	5
161	Should biologics for psoriasis be interrupted in the era of COVID-19?. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1217-1218	4.5	119

160	Osteoporosis and bone health in autoimmune blistering skin disease-an evidenced based review. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 2745-2756	4.6	
159	Multiple milia formation in blistering diseases. <i>International Journal of Women's Dermatology</i> , <b>2020</b> , 6, 199-202	2	0
158	Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 158	4.2	3
157	Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13956	2.2	4
156	Successful dapsone therapy in inherited epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e333-e334	4.6	1
155	Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris. <i>International Journal of Women's Dermatology</i> , <b>2020</b> , 6, 306-310	2	7
154	Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution". <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, e215	4.5	2
153	Treatment considerations for patients with pemphigus during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, e235-e236	4.5	42
152	Where do we stand as dermatologists in combat with COVID-19. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13638	2.2	7
151	Mycobacterium chelonae infection mimicking Demodex folliculitis. <i>Clinical and Experimental Dermatology</i> , <b>2020</b> , 45, 469-470	1.8	
150	A prickly souvenir from a hedgehog cactinea manuum secondary to Trichophyton erinacei via international spread. <i>Clinical and Experimental Dermatology</i> , <b>2020</b> , 45, 459-461	1.8	
149	The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 1	4.2	41
148	Predatory journals: The silent intruder. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13214	2.2	
147	Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. <i>Veterinary Dermatology</i> , <b>2020</b> , 31, 291-e71	1.8	9
146	Drug-related adverse effects of vismodegib and sonidegib for locally advanced or metastatic basal cell carcinoma. <i>Australasian Journal of Dermatology</i> , <b>2020</b> , 61, 176-177	1.3	4
145	Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 614-627	4	179
144	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic-Consensus: Recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1222-1224	4.5	5
143	Dermatology and specialty rotations: COVID-19 may reemphasize the importance of internal medicine. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13996	2.2	2

142	Splicing of the cake can affect the severity of epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1879-1880	4.6	1
141	COVID-19 and immunosuppressive therapy in dermatology. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14140	2.2	3
140	Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. <i>Orphanet Journal of Rare Diseases</i> , <b>2020</b> , 15, 190	4.2	2
139	Role of music therapy in reducing the burden of dermatological diseases during COVID-19. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14086	2.2	2
138	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1900-1913	4.6	60
137	Financial burden of epidermolysis bullosa on patients in the United States. <i>Pediatric Dermatology</i> , <b>2020</b> , 37, 1198-1201	1.9	5
136	Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. <i>Veterinary Dermatology</i> , <b>2020</b> , 31, 410-e110	1.8	7
135	Outcomes and Predictors for Re-stenosis of Esophageal Stricture in Epidermolysis Bullosa: A Multicenter Cohort Study. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2020</b> , 71, 310-314	2.8	5
134	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 575-585.e1	4.5	127
133	Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 173-182	11.5	108
132	Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 153-160	4.6	15
131	Novel diagnostic method to differentiate antilaminin-332 pemphigoid from other forms of pemphigoid. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 270-271	4	1
130	Reply to: "Biologics for psoriasis during COVID-19 outbreak". <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, e219	4.5	2
129	Patients left behind: Rare dermatologic conditions miss the orphan drug development boom. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 1025-1026	4.5	
128	What is novel in the clinical management of pemphigus. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 973-980	3.8	7
127	Pathogenesis and clinical features of alopecia in epidermolysis bullosa: A systematic review. <i>Pediatric Dermatology</i> , <b>2019</b> , 36, 430-436	1.9	1
126	Review of autoimmune blistering diseases: the Pemphigoid diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 1685-1694	4.6	29
125	Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues. <i>International Journal of Women's Dermatology</i> , <b>2019</b> , 5, 166-170	2	5

124	Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report. <i>International Journal of Women's Dermatology</i> , <b>2019</b> , 5, 179-180	2	2
123	Atopic Dermatitis Outcome Measures <b>2019</b> , 1-28		
122	Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidence-based review. <i>Experimental Dermatology</i> , <b>2019</b> , 28, 1122-1130	4	6
121	Inter-rater reliability of the BIOCHIP indirect immunofluorescence dermatology mosaic in bullous pemphigoid and pemphigus patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 2327-2333	4.6	5
120	Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. <i>Anais Brasileiros De Dermatologia</i> , <b>2019</b> , 94, 399-404	1.6	6
119	Atopic Dermatitis Outcome Measures <b>2019</b> , 1-28		
118	Pemphigus vulgaris accompanied with amyotrophic lateral sclerosis: a rare coincidence or pathogenic relationship?. <i>European Journal of Dermatology</i> , <b>2019</b> , 29, 435-436	0.8	
117	Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis <b>2019</b> , 777-784		1
116	Epidermolysis Bullosa Patients' Perception of Surgical Wound and Scar Healing. <i>Dermatologic Surgery</i> , <b>2019</b> , 45, 280-289	1.7	1
115	Diagnostic Criteria and Phenotypes of Pemphigoid and the Association With Gliptins. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 147-148	5.1	1
114	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 31-37	4.3	33
113	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 768-775	4	71
112	A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases. <i>Orphanet Journal of Rare Diseases</i> , <b>2018</b> , 13, 83	4.2	8
111	The effect of autoimmune blistering diseases on work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 1959-1966	4.6	6
110	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	53
109	Chinese version of the treatment of autoimmune bullous disease quality of life questionnaire: Reliability and validity. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , <b>2018</b> , 84, 431-436	0.8	2
108	Topical Corticosteroids in Blistering Diseases <b>2018</b> , 91-100		3
107	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 30-41	4	35

106	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2018</b> , 54, 26-51	12.3	94
105	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 306	4.9	15
104	Is the Oral Disease Severity Score going to be useful for dermatologists when assessing pemphigus?. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 816-817	4	2
103	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 543-546	2.4	80
102	Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. <i>Advances in Medical Sciences</i> , <b>2017</b> , 62, 92-96	2.8	18
101	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. <i>BMC Cancer</i> , <b>2017</b> , 17, 332	4.8	196
100	Increasing prevalence but not incidence of psoriasis in the U.K. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 568-569	4	
99	A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 985-992	4	21
98	Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. <i>Acta Dermato-Venereologica</i> , <b>2017</b> , 97, 1145-1147	2.2	7
97	Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation. <i>Orphanet Journal of Rare Diseases</i> , <b>2017</b> , 12, 189	4.2	3
96	An Atypical Localized Form of Hidradenitis Suppurativa of the Jawline and Neck Mimicking Severe Cystic Acne on Presentation. <i>Skin Appendage Disorders</i> , <b>2017</b> , 3, 215-218	1.4	4
95	Highly Resistant Acrodermatitis Continua of Hallopeau and Pustular Psoriasis. <i>Skin Appendage Disorders</i> , <b>2017</b> , 3, 179-181	1.4	2
94	Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire. <i>Health and Quality of Life Outcomes</i> , <b>2017</b> , 15, 31	3	8
93	Digenic inheritance in epidermolysis bullosa simplex involving two novel mutations in KRT5 and KRT14. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 262-264	4	7
92	The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 692-698	4.6	13
91	The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?. <i>Acta Dermato-Venereologica</i> , <b>2017</b> , 97, 24-31	2.2	21
90	Multiple sclerosis is the neurological disorder most highly associated with bullous pemphigoid. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 1428-1429	4	3
89	A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 595-603	4.6	10



88	Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 56-67	4	70
87	Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. <i>Pathology</i> , <b>2016</b> , 48, 720-726	1.6	7
86	Cover Image: The many faces of sarcoidosis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 1111-1112	4	
85	Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese. <i>International Journal of Dermatology</i> , <b>2016</b> , 55, e94-9	1.7	16
84	Suppression of TGF $\beta$ and Angiogenesis by Type VII Collagen in Cutaneous SCC. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	48
83	Pigmented Hair-Thickening Fibers: A Camouflage Technique for Alopecia in Patients with Epidermolysis Bullosa. <i>Skin Appendage Disorders</i> , <b>2016</b> , 1, 153-5	1.4	4
82	What is the true mortality from pemphigus?. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 1185-6	4	3
81	Marked intrafamilial phenotypic heterogeneity in dystrophic epidermolysis bullosa caused by inheritance of a mild dominant glycine substitution and a novel deep intronic recessive COL7A1 mutation. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 1122-5	4	9
80	Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 142-9	4	52
79	Chlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation - a case series of four patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 1239-42	4.6	6
78	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 69-74	4	90
77	Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia. <i>Australasian Journal of Dermatology</i> , <b>2016</b> , 57, 167-74	1.3	42
76	Cover image: Unpeeling the layers of harlequin ichthyosis. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 1160-1	4	1
75	Innate sensing of microbial products promotes wound-induced skin cancer. <i>Nature Communications</i> , <b>2015</b> , 6, 5932	17.4	80
74	Multiple cutaneous reticulohistiocytomas successfully treated with topical psoralen plus ultraviolet A therapy combined with intralesional injections of triamcinolone acetonide. <i>JAAD Case Reports</i> , <b>2015</b> , 1, 157-9	1.4	3
73	Age and etiology of childhood epidermolysis bullosa mortality. <i>Journal of Dermatological Treatment</i> , <b>2015</b> , 26, 178-82	2.8	19
72	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 992-1002	4.5	118
71	Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA. <i>Quality of Life Research</i> , <b>2015</b> , 24, 2257-60	3.7	20

70	A pilot comparison study of four clinician-rated atopic dermatitis severity scales. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 488-97	4	26
69	Retrospective evidence on outcomes and experiences of pregnancy and childbirth in epidermolysis bullosa in Australia and New Zealand. <i>International Journal of Women's Dermatology</i> , <b>2015</b> , 1, 26-30	2	2
68	Recessive dystrophic epidermolysis bullosa (RDEB) complicated by secondary hepatic amyloidosis. <i>JAAD Case Reports</i> , <b>2015</b> , 1, 337-9	1.4	2
67	Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa. <i>European Journal of Dermatology</i> , <b>2015</b> , 25 Suppl 1, 30-2	0.8	15
66	Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. <i>Journal of Clinical Neuroscience</i> , <b>2015</b> , 22, 1992-3	2.2	1
65	Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. <i>International Journal of Women's Dermatology</i> , <b>2015</b> , 1, 37-40	2	14
64	The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area. <i>International Journal of Women's Dermatology</i> , <b>2015</b> , 1, 150-154	2	10
63	Burden of disease scoring in epidermolysis bullosa. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 1357-8	4	1
62	Advances in understanding and managing bullous pemphigoid. <i>F1000Research</i> , <b>2015</b> , 4,	3.6	9
61	Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence <b>2015</b> , 459-468		2
60	Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 168-74	4.5	93
59	Outcome measures for autoimmune blistering diseases. <i>Journal of Dermatology</i> , <b>2015</b> , 42, 31-6	1.6	24
58	Cytoskeletal protein Flightless I inhibits apoptosis, enhances tumor cell invasion and promotes cutaneous squamous cell carcinoma progression. <i>Oncotarget</i> , <b>2015</b> , 6, 36426-40	3.3	20
57	Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 89-97.e1-13	4.5	37
56	Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 1103-26	4.5	596
55	Management of pemphigus. <i>F1000prime Reports</i> , <b>2014</b> , 6, 32		10
54	Screening for infections prior to initiating immunosuppressive treatment for patients with autoimmune blistering diseases. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 1285-6	4	
53	Health-related quality of life in epidermolysis bullosa: Validation of the Dutch QOLEB questionnaire and assessment in the Dutch population. <i>Acta Dermato-Venereologica</i> , <b>2014</b> , 94, 442-7	2.2	17

52	Inherited epidermolysis bullosa. <i>Journal of the Egyptian Women's Dermatologic Society</i> , <b>2014</b> , 11, 1-13	0.3	1
51	Bullous pemphigoid: therapeutic algorithm and practical management. <i>Expert Opinion on Orphan Drugs</i> , <b>2013</b> , 1, 405-412	1.1	1
50	A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 898-908.e7	4.5	78
49	Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 208-10	4	15
48	The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 1000-6	4	43
47	Management of epidermolysis bullosa. <i>Expert Opinion on Orphan Drugs</i> , <b>2013</b> , 1, 279-293	1.1	5
46	Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 1186-91	5.1	52
45	A quantitative approach to histopathological dissection of elastin-related disorders using multiphoton microscopy. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 869-79	4	21
44	Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 67, 1111-7	9.3	137
43	Diagnosis and clinical features of pemphigus vulgaris. <i>Immunology and Allergy Clinics of North America</i> , <b>2012</b> , 32, 233-43, v-vi	3.3	24
42	Autoimmune diseases of the skin. <i>Immunology and Allergy Clinics of North America</i> , <b>2012</b> , 32, xiii-xiv	3.3	2
41	Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 479-85	4.5	203
40	Inherited epidermolysis bullosa: new diagnostic criteria and classification. <i>Clinics in Dermatology</i> , <b>2012</b> , 30, 70-7	3	99
39	Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. <i>Cancer Research</i> , <b>2012</b> , 72, 3522-34	10.1	83
38	The International Pemphigus and Pemphigoid Foundation. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 655-7	4.2	1
37	Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 591-8	4.2	17
36	Diagnosis and clinical features of pemphigus vulgaris. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 373-80, vii	4.2	43
35	A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 903-8	4.5	100

34	Advancement of women in dermatology. <i>International Journal of Dermatology</i> , <b>2011</b> , 50, 593-600	1.7	6
33	Outcomes of 11 pregnancies in three patients with recessive forms of epidermolysis bullosa. <i>British Journal of Dermatology</i> , <b>2011</b> , 165, 700-1	4	8
32	A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2011</b> , 25, 117-8	4.6	1
31	Evidence-based management of bullous pemphigoid. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 613-20	4.2	27
30	Hair loss in autoimmune cutaneous bullous disorders. <i>Dermatologic Clinics</i> , <b>2011</b> , 29, 503-9, xi	4.2	13
29	Diagnosis and Prevention of Bullous Diseases <b>2011</b> , 115-135		
28	Diagnosis and Prevention of Bullous Diseases <b>2011</b> , 53-73		
27	Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. <i>Archives of Dermatology</i> , <b>2010</b> , 146, 635-40		57
26	No evidence that human papillomavirus is responsible for the aggressive nature of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 2853-5	4.3	6
25	Quality of life measurements in epidermolysis bullosa: tools for clinical research and patient care. <i>Dermatologic Clinics</i> , <b>2010</b> , 28, 185-90	4.2	22
24	Epidermolysis bullosa in Australia and New Zealand. <i>Dermatologic Clinics</i> , <b>2010</b> , 28, 433-8, xvi	4.2	12
23	Alopecia in epidermolysis bullosa. <i>Dermatologic Clinics</i> , <b>2010</b> , 28, 165-9	4.2	17
22	How to take skin biopsies for epidermolysis bullosa. <i>Dermatologic Clinics</i> , <b>2010</b> , 28, 197-200, vii	4.2	31
21	Dermatologic Clinics. Epidermolysis bullosa: part II--diagnosis and management. Preface. <i>Dermatologic Clinics</i> , <b>2010</b> , 28, xix	4.2	2
20	Treatment of pemphigus vulgaris and pemphigus foliaceus. <i>Expert Review of Dermatology</i> , <b>2009</b> , 4, 469-481		4
19	Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. <i>British Journal of Dermatology</i> , <b>2009</b> , 161, 1323-30	4	76
18	Reliability and convergent validity of two outcome instruments for pemphigus. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 2404-10	4.3	149
17	Naevus of Ota presenting in two generations: a mother and daughter. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2009</b> , 23, 102-4	4.6	8

16	Mucous membrane pemphigoid: are laminin 5 antibodies a risk factor for laryngeal involvement?. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2009</b> , 23, 169-70	4.6	9
15	Interventions for pemphigus vulgaris and pemphigus foliaceus. <i>The Cochrane Library</i> , <b>2009</b> , CD006263	5.2	68
14	A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2008</b> , 22, 1302-11	4.6	163
13	Clinical heterogeneity in recessive epidermolysis bullosa due to mutations in the keratin 14 gene, KRT14. <i>Clinical and Experimental Dermatology</i> , <b>2008</b> , 33, 689-97	1.8	30
12	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 1043-6	4.5	372
11	The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 931-50	4.5	690
10	Treatment of pemphigus: the need for more evidence. <i>Archives of Dermatology</i> , <b>2008</b> , 144, 100-1		15
9	A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. <i>British Journal of Dermatology</i> , <b>2007</b> , 157, 954-9	4	52
8	A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. <i>American Journal of Dermatopathology</i> , <b>2006</b> , 28, 387-94	0.9	51
7	A complicated blistering disease case demonstrating the usefulness of immunoblotting and ELISA for the diagnosis of immunobullous diseases. <i>Australasian Journal of Dermatology</i> , <b>2006</b> , 47, A57-A57	1.3	2
6	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1214-27	4.27	44
5	Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. <i>The Cochrane Library</i> , <b>2003</b> , CD004056	5.2	32
4	Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. <i>Human Genetics</i> , <b>2002</b> , 110, 41-51	6.3	111
3	Epidermolysis bullosa with congenital pyloric atresia: novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations. <i>Pediatric Research</i> , <b>2001</b> , 49, 618-26	3.2	76
2	Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. <i>Journal of Investigative Dermatology</i> , <b>1993</b> , 100, 618-22	4.3	70
1	Celebrating Outstanding Science at the European Academy of Dermatology and Venereology 30th Anniversary Congress 24-28		